-+ 0.00%
-+ 0.00%
-+ 0.00%

The Zhitong Finance App learned that on December 9, Hualing Pharmaceutical (02552.HK) announced that the second-generation glucokinase activator (GKA) HMS1005 (formerly known as HM-002-1005) independently developed by the company in the US has successfully completed the administration of the first trial participants in the phase Ib multiple dose escalation (MAD) trial. Hualing Pharmaceutical has made further progress in expanding the overseas diabetes market and continues to lead a new path of global GKA development.

Zhitongcaijing·12/10/2025 01:41:06
Listen to the news
The Zhitong Finance App learned that on December 9, Hualing Pharmaceutical (02552.HK) announced that the second-generation glucokinase activator (GKA) HMS1005 (formerly known as HM-002-1005) independently developed by the company in the US has successfully completed the administration of the first trial participants in the phase Ib multiple dose escalation (MAD) trial. Hualing Pharmaceutical has made further progress in expanding the overseas diabetes market and continues to lead a new path of global GKA development.